EUVIMEDEUVIMED entdecken
Open Access

The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis

Ting Jia, Tong Xu, Bart Smeets, Eva Miriam Buhl, Marcus Johannes Moeller, Jürgen Floege, Barbara Mara Klinkhammer iD, Peter Boor iD

Journal of the American Society of Nephrology · 2023-02 · 34 (2) · 241-257

DOI: 10.1681/asn.2022040491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 09.11.2022. Verfasst von Ting Jia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany. Hauptthemen laut MEDLINE: Glomerulosclerosis, Focal Segmental, Podocytes. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: German Federal Ministries of Education and Research, German Research Foundation, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Significance Statement We investigated the role of the profibrotic PDGF in the development and progression of FSGS in a murine model resembling human FSGS. Injured podocytes expressed PDGF-B, inducing parietal epithelial cell activation, proliferation, and a profibrotic switch–driving FSGS. Therapeutic inhibition of PDGF-B significantly reduced proteinuria and FSGS, suggesting that inhibition of the PDGF signaling pathway might be a potential novel treatment for patients with FSGS.

Background

FSGS is the final common pathway to nephron loss in most forms of severe or progressive glomerular injury. Although podocyte injury initiates FSGS, parietal epithelial cells (PECs) are the main effectors. Because PDGF takes part in fibrotic processes, we hypothesized that the ligand PDGF-B and its receptor PDGFR- β participate in the origin and progression of FSGS.

Methods

We challenged Thy1.1 transgenic mice, which express Thy1.1 in the podocytes, with anti-Thy1.1 antibody to study the progression of FSGS. We investigated the role of PDGF in FSGS using challenged Thy1.1 mice, 5/6 nephrectomized mice, Col4−/− (Alport) mice, patient kidney biopsies, and primary murine PECs, and challenged Thy1.1 mice treated with neutralizing anti–PDGF-B antibody therapy.

Results

The unchallenged Thy1.1 mice developed only mild spontaneous FSGS, whereas challenged mice developed progressive FSGS accompanied by a decline in kidney function. PEC activation, proliferation, and profibrotic phenotypic switch drove the FSGS. During disease, PDGF-B was upregulated in podocytes, whereas PDGFR- β was upregulated in PECs from both mice and patients with FSGS. Short- and long-term treatment with PDGF-B neutralizing antibody improved kidney function and reduced FSGS, PEC proliferation, and profibrotic activation. In vitro , stimulation of primary murine PECs with PDGF-B recapitulated in vivo findings with PEC activation and proliferation, which was inhibited by PDGF-B antibody or imatinib.

Conclusion

PDGF-B–PDGFR- β molecular crosstalk between podocytes and PECs drives glomerulosclerosis and the progression of FSGS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulosclerosis, Focal SegmentalPodocytesMiceAnimalsPlatelet-Derived Growth FactorKidney GlomerulusEpithelial CellsMice, Transgenic

Substanzen

Platelet-Derived Growth Factor

Autor:innen und Institutionen

  • Institute of Pathology, RWTH Aachen University Hospital, Aachen, Germany.
  • Department of Nephrology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • Electron Microscopy Facility, RWTH Aachen University Hospital, Aachen, Germany.
  • Department of Nephrology and Immunology, RWTH Aachen University Hospital, Aachen, Germany.
  • Heisenberg Chair for Preventive and Translational Nephrology, RWTH Aachen University Hospital, Aachen, Germany.

ORCID-Profile: Barbara Mara Klinkhammer, Peter Boor

Förderung

  • German Federal Ministries of Education and Research
  • German Research Foundation
  • European Research Council

Zitieren

APA

Jia, T., Xu, T., Smeets, B., Buhl, E. M., Moeller, M. J., Floege, J., Klinkhammer, B. M., & Boor, P. (2023). The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis. Journal of the American Society of Nephrology, 34(2), 241-257. https://doi.org/10.1681/asn.2022040491

Vancouver

Jia T, Xu T, Smeets B, Buhl EM, Moeller MJ, Floege J, et al. The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis. Journal of the American Society of Nephrology. 2023;34(2):241-257. doi:10.1681/asn.2022040491

BibTeX
@article{Jia2023,
  author = {Jia, Ting and Xu, Tong and Smeets, Bart and Buhl, Eva Miriam and Moeller, Marcus Johannes and Floege, Jürgen and Klinkhammer, Barbara Mara and Boor, Peter},
  title = {The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis},
  journal = {Journal of the American Society of Nephrology},
  year = {2023},
  volume = {34},
  number = {2},
  pages = {241--257},
  doi = {10.1681/asn.2022040491}
}
Kostenlos starten →